Abstract:Conventionally, the classification of lung cancer and many other malignancies is determined by the histology of a tumor. Large cell neuroendocrine carcinoma (LCNEC) is traditionally classified as a histological variant of large cell carcinoma (LCC), which is a subtype of non-small cell lung cancer (NSCLC). However, LCNEC exhibits differential cytological, morphological, clinical and biological features than those of classic LCC, thus rendering controversies regarding its classification. In 2015, with the integration of immunohistochemical analyses, the World Health Organization (WHO) has re-classified LCNEC under neuroendocrine tumors. Due to the rareness of LCNEC, few studies have been conducted on the molecular genetic profiling of LCNEC. In this study, we characterized molecular signature associated with a cohort of LCNEC, SCLC and LCC using capture-based targeted sequencing. We performed capture-based targeted sequencing on 30 surgically resected samples from patients with lung cancer using BurningRock Biotech’s OncoScreen Panel. This panel, consisting of all exons and critical introns of 295 genes, covering multiple classes of somatic mutations, including single nucleotide variation (SNVs), rearrangements, copy number variations (CNVs) and insertions and deletions (INDELs), can be used to detect genetic alterations both qualitatively and quantitatively. Among the 30 patients, 15 of them were diagnosed with LCNEC, 5 with LCC and 10 with small cell lung cancer (SCLC). While no statistically significant difference was observed in total number of mutations among the three subtypes, LCC carries the most number of somatic mutations followed by LCNEC then SCLC. Overall, we identified 331 mutations with TP53 being the most frequently mutated gene in all three subtypes. Genes with recurrent somatic mutations detected in LCNEC, but not in LCC or SCLC include RUNX1, ERBB4, BRCA1, and EPHA3. Copy number analysis revealed a higher prevalence of CNV in LCNEC, with 60% of cases harboring such alteration. There is no common CNVs shared among all three subtypes. NFкBIA amplification is the only common CNV found in both LCNEC and LCC; and AKT2 amplification is shared by LCNEC and SCLC. Most CNVs are subtype-specific. Interestingly, one RET-fusion was discovered in one LCC sample and one EGFR exon 19 deletion accompanied by EGFR copy number amplification was discovered in one LCNEC sample. Targeted deep sequencing reveals distinct genetic profile for LCNEC compared to LCC and SCLC. LCNEC harbors more CNV and contains a panel of genes, including RUNX1, ERBB4, BRCA1 and EPHA3 that are more frequently mutated comparing to LCC and SCLC.

P1.02-075 Analysis of Driver Genes Alteration and Clinicopathological Features in Pulmonary Marker-Null Large Cell Carcinoma: Topic: Other Mutations in Thoracic Malignancies

Clinicopathological And Genetic Characteristics Of Pulmonary Large Cell Carcinoma Under 2015 Who Classification: A Pilot Study

Clinical characteristics and gene mutation analysis of clear cell tumor of the lung

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Clinicopathological Analysis of Large Cell Lung Carcinomas Definitely Diagnosed According to the New World Health Organization Criteria.

Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives

Incidence of Inconsistent Driver Mutations Between Multiple Lung Ground-Glass Nodules in Patients with Non-Small Cell Lung Cancer

Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?

Clinical Genetic Features and Related Survival Implications in Patients with Surgically Resected Large-Cell Lung Cancer

Association Between Certain Non–small Cell Lung Cancer Driver Mutations and Predictive Markers for Chemotherapy or Programmed Death‐ligand 1 Inhibition

[Large-Cell Lung Carcinoma by the 2015 WHO Classification: a Clinicopathologic Analysis of 93 Cases].

MA11.01 Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture-Based Targeted Sequencing

Clinicopathological and Molecular Characteristics Associated with PD-L1 Expression in Non-Small Cell Lung Cancer: a Large-Scale, Multi-Center, Real-World Study in China

P3.12-12 Genomic Profiling of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) Reveals Distinct Mutational Landscape

[Clinicopathologic Features and Genetic Profile of the Redefined Large Cell Lung Carcinoma].

The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients

A Multicenter Analysis of Genomic Profiles and PD-L1 Expression of Primary Lymphoepithelioma-Like Carcinoma of the Lung

Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas

Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma

Comprehensive Investigation of Clinicopathologic Features, Oncogenic Driver Mutations and Immunohistochemical Markers in Peripheral Lung Squamous Cell Carcinoma.

16PCOMPREHENSIVE ANALYSIS OF DRIVER MUTATIONS IN CHINESE SQUAMOUS CELL LUNG CARCINOMAS BY TARGETED NEXT-GENERATION SEQUENCING